Alpha Cognition Inc.
Alpha Cognition (ACOG) granted 20,000 stock options to a new employee, exercisable at $9.27 per share, vesting over three years. The options comply with Nasdaq Rule 5635(c)(4) and are part of the company's 2026 Inducement Grant Plan. ACOG focuses on neurodegenerative disease treatments, including ZUNVEYL for Alzheimer's and ALPHA-1062 for Alzheimer's and mTBI.
Wills Robert James purchased 10,000 shares of Alpha Cognition Inc. (ACOG) at $9.62 on 2026-08-21.
B.Riley initiated coverage on Alpha Cognition (NASDAQ:ACOG) with a buy rating and $21 price target, citing strong revenue growth and high gross margins. The company reported $6M in Q2 2026 revenue, up 71% sequentially, driven by its Alzheimer's drug ZUNVEYL. Analysts highlight commercial momentum despite challenges in payer expansion.
Over the past 7 days, alphai's AI scored 1 news story mentioning ACOG (Alpha Cognition Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent ACOG coverage spans earnings, insider activity and financial news.
In the last 30 days, ACOG insiders filed 1 SEC Form 4 transaction — 1 purchase ($96K) and no sales. The most active reporter was Wills Robert James with 1 filing.
Small dilution from a modest option grant; limited immediate price impact.
Small insider buy by a director may signal confidence but the transaction size is modest.
Strong quarterly revenue growth and analyst upgrade suggest upside potential.
The article provides incremental operating datapoints (revenue, bottle growth, prescriber/facility adoption) plus guidance cuts, supporting a more constructive near-term demand and cost outlook.
Near-term upside depends less on demand prints and more on payer formulary coverage progress; clinical readouts and lower opex guidance support the longer runway.
alphai scores every news story that mentions ACOG with an AI model for sentiment and relevance, and aggregates insider trades from Alpha Cognition Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alpha Cognition (ACOG) granted 20,000 stock options to a new employee, exercisable at $9.27 per share, vesting over three years. The options comply with Nasdaq Rule 5635(c)(4) and are part of the company's 2026 Inducement Grant Plan. ACOG focuses on neurodegenerative disease treatments, including ZUNVEYL for Alzheimer's and ALPHA-1062 for Alzheimer's and mTBI.
1 min readWills Robert James purchased 10,000 shares of Alpha Cognition Inc. (ACOG) at $9.62 on 2026-08-21.
1 min readB.Riley initiated coverage on Alpha Cognition (NASDAQ:ACOG) with a buy rating and $21 price target, citing strong revenue growth and high gross margins. The company reported $6M in Q2 2026 revenue, up 71% sequentially, driven by its Alzheimer's drug ZUNVEYL. Analysts highlight commercial momentum despite challenges in payer expansion.
2 min readStonegate Capital Partners updated coverage of Alpha Cognition Inc. (NASDAQ: ACOG), citing 2Q26 ZUNVEYL progress. Net product revenue rose 71% q/q to $6.0M, bottles up 37% to 8,294, and June was the strongest month since launch. Adoption broadened with 1,347 prescribers and 1,095 LTC facilities. Stonegate said FY26 R&D and SG&A guidance was lowered to $50M-$54M while keeping a 2027 profitability target.
4 min readAlpha Cognition (NASDAQ:ACOG) said ZUNVEYL demand rose each month in Q2, with June the strongest month to date, and management attributed growth to demand rather than wholesaler or pharmacy stocking. Payer formulary activation lagged expectations, with payer access the key near-term friction. The company reported BEACON study positive top-line results, lowered 2026 operating expense guidance to $50M-$54M, and had $41.4M cash as of June 30.
6 min readAlpha Cognition (ACOG) shares rose about 12.1% pre-open after its Q2 2026 earnings call. ZUNVEYL net product revenue was about $6.0M, up 71% sequentially and from $1.7M in Q2 2025. Net loss narrowed to $8.8M ($0.40/share). Gross product margin was ~94%, and full-year 2026 operating expense guidance was cut to $50M-$54M; profitability target remains 2027.
4 min readAlpha Cognition (NASDAQ: ACOG) reported Q2 2026 results for ZUNVEYL. Net product revenue rose about 71% QoQ to $6.0M. Bottles dispensed increased 37% to 8,294, with June monthly demand at 2,997. Cash and cash equivalents were $41.4M at June 30. The company cut full-year 2026 R&D and SG&A guidance to $50–$54M.
7 min readOpaleye Management Inc. purchased 52,900 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $8.00 ($7.92–$8.00, $0.42M total) across 2 trades over 2026-07-31 to 2026-08-03.
2 min readAlpha Cognition Inc. (NASDAQ: ACOG) said the European Patent Office granted a European patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in treating mild-to-moderate Alzheimer’s disease. The patent covers specific solid form, compositions, manufacturing and medical-use claims, with potential protection into 2042, subject to requirements.
3 min readOpaleye Management Inc. purchased 200,086 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $7.82 ($7.80–$7.83, $1.57M total) across 3 trades over 2026-07-22 to 2026-07-23.
2 min read
